Effect of ranolazine in preventing postoperative atrial fibrillation in patients undergoing coronary revascularization surgery.
Title | Effect of ranolazine in preventing postoperative atrial fibrillation in patients undergoing coronary revascularization surgery. |
Publication Type | Journal Article |
Year of Publication | 2013 |
Authors | Tagarakis, G. I., Aidonidis I., Daskalopoulou S. S., Simopoulos V., Liouras V., Daskalopoulos M. E., Parisis C., Papageorgiou K., Skoularingis I., Triposkiadis F., Molyvdas P-A., & Tsilimingas N. B. |
Journal | Curr Vasc Pharmacol |
Volume | 11 |
Issue | 6 |
Pagination | 988-91 |
Date Published | 2013 Nov |
ISSN | 1875-6212 |
Keywords | Acetanilides, Aged, Anti-Arrhythmia Agents, Atrial Fibrillation, Coronary Artery Bypass, Female, Humans, Male, Middle Aged, Percutaneous Coronary Intervention, Piperazines, Postoperative Complications, Preoperative Care, Ranolazine, Single-Blind Method, Treatment Outcome |
Abstract | BACKGROUND/OBJECTIVE: Ranolazine is a new anti-ischemic agent approved for chronic angina with additional electrophysiologic properties. The purpose of the present trial was to investigate its effect in preventing postoperative atrial fibrillation (POAF) after on-pump coronary artery bypass graft (CABG) surgery.METHODS: In the current prospective, randomized, (1 active: 2 control), single-blind (outcome assessors), single-centre clinical trial we recruited consecutive eligible patients scheduled for elective on-pump CABG. Participants were assigned to receive either oral ranolazine 375 mg twice daily for 3 days prior to surgery and until discharge, or to receive usual care. Patients were monitored for the development of POAF.RESULTS: We enrolled 102 patients. Significantly lower incidence of POAF was noted in the ranolazine group compared with the control group (3 out of 34 patients, 8.8%, vs 21 out of 68 patients, 30.8%; p< 0.001). Mean values of left atrial diameter and left ventricular ejection fraction between the control and the ranolazine group were not significantly different.CONCLUSION: Our findings suggest a protective role of oral ranolazine when administered in a moderate dose preoperatively in patients undergoing on-pump CABG surgery. Future studies based on a wider sample of patients will eventually support our conclusions. |
Alternate Journal | Curr Vasc Pharmacol |
PubMed ID | 23140547 |